Butyrate as a Potential Modulator in Gynecological Disease Progression
Nutrients · 04.12.2024 · 16 (23) · 4196
DOI: 10.3390/nu16234196 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 04.12.2024. Verfasst von Nayeon Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science Education, Ewha Womans University, Seoul 03760, Republic of Korea. Hauptthemen laut MEDLINE: Butyrates, Polycystic Ovary Syndrome, Disease Progression, Endometriosis. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Basic Science Research Program through the National Research Foundation of Korea (NRF), Ewha Womans University Research Grant of 2022.
Abstract (Originalsprache)
This review investigates the therapeutic potential of butyrate, a short-chain fatty acid (SCFA) produced by gut microbiota, in the prevention and treatment of various gynecological diseases, including polycystic ovary syndrome (PCOS), endometriosis, and gynecologic cancers like cervical and ovarian cancer. These conditions often pose treatment challenges, with conventional therapies offering limited and temporary relief, significant side effects, and a risk of recurrence. Emerging evidence highlights butyrate’s unique biological activities, particularly its role as a histone deacetylase (HDAC) inhibitor, which allows it to modulate gene expression, immune responses, and inflammation. In PCOS, butyrate aids in restoring hormonal balance, enhancing insulin sensitivity, and reducing chronic inflammation. For endometriosis, butyrate appears to suppress immune dysregulation and minimize lesion proliferation. Additionally, in cervical and ovarian cancers, butyrate demonstrates anticancer effects through mechanisms such as cell cycle arrest, apoptosis induction, and suppression of tumor progression. Dietary interventions, particularly high-fiber and Mediterranean diets, that increase butyrate production are proposed as complementary approaches, supporting natural microbiota modulation to enhance therapeutic outcomes. However, butyrate’s short half-life limits its clinical application, spurring interest in butyrate analogs and probiotics to maintain stable levels and extend its benefits. This review consolidates current findings on butyrate’s multifaceted impact across gynecological health, highlighting the potential for microbiota-centered therapies in advancing treatment strategies and improving women’s reproductive health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Science Education, Ewha Womans University, Seoul 03760, Republic of Korea.
ORCID-Profile: Changwon Yang
Förderung
- Ministry of Education
- Basic Science Research Program through the National Research Foundation of Korea (NRF)
- Ewha Womans University Research Grant of 2022
Zitieren
APA
Kim, N., & Yang, C. (2024). Butyrate as a Potential Modulator in Gynecological Disease Progression. Nutrients, 16(23), 4196. https://doi.org/10.3390/nu16234196
Vancouver
Kim N, Yang C. Butyrate as a Potential Modulator in Gynecological Disease Progression. Nutrients. 2024;16(23):4196. doi:10.3390/nu16234196
BibTeX
@article{Kim2024,
author = {Kim, Nayeon and Yang, Changwon},
title = {Butyrate as a Potential Modulator in Gynecological Disease Progression},
journal = {Nutrients},
year = {2024},
volume = {16},
number = {23},
pages = {4196},
doi = {10.3390/nu16234196}
}
EUVIMED